论文部分内容阅读
目的探讨巴曲抗栓酶对急性缺血性脑卒中病人血清补体末端复合物(TCC)和血浆纤维蛋白原(FIB)含量变化的影响。方法92例病人随机分为对照组和治疗组,2组均给予综合治疗,治疗组加用巴曲抗栓酶。在确诊当时及d 6、d 10各留取血液标本测定血清TCC水平,用药前及以后每次用药前检测FIB水平,分别于治疗前、d 7、d 14进行神经功能缺损评分。结果缺血性脑卒中发作初期血浆TCC、FIB含量2组差别无显著意义(P>0.05),2组TCC含量d 6时均增高,d 10天仍高于治疗前水平。但是在治疗后d 10治疗组TCC浓度(478±s 47)ng·L~(-1)明显低于对照组(638±39)ng·L~(-1)(P<0.01);经治疗后治疗组FIB浓度明显降低(P<0.01);治疗组神经功能缺损评分明显低于对照组(P<0.01)。结论巴曲抗栓酶能明显降低急性缺血性脑卒中病人血清TCC、FIB水平,有利于减轻炎症反应,促进神经功能恢复。
Objective To investigate the effect of batroxobin on changes of serum complement (TCC) and fibrinogen (FIB) in patients with acute ischemic stroke. Methods Ninety-two patients were randomly divided into control group and treatment group. Both groups were given comprehensive treatment. The treatment group was treated with batroxobin. Serum TCC levels were measured at the time of diagnosis and at each of d 6 and d 10 serum samples. FIB levels were measured before and after each drug administration, and neurological deficit scores were measured before treatment, d 7 and d 14 respectively. Results The plasma levels of TCC and FIB in the early stage of ischemic stroke were not significantly different between the two groups (P> 0.05). The levels of TCC in both groups increased at d 6 and remained higher than those before treatment at d 10. However, after treatment, the TCC concentration (478 ± 477 ng · L -1) in d 10 treatment group was significantly lower than that in control group (638 ± 39 ng · L -1) (P <0.01) The FIB concentration in the post-treatment group was significantly lower (P <0.01). The score of neurological deficit in the treatment group was significantly lower than that of the control group (P <0.01). Conclusion Batroxobin can significantly reduce serum TCC and FIB levels in patients with acute ischemic stroke, which is beneficial to reduce the inflammatory reaction and promote the recovery of neurological function.